FDA Eases Rules for Certifying Medical Gases
Published Date: 2/12/2026
Notice
Summary
The FDA just dropped a fresh draft guide on how companies should get their medical gases certified and report yearly. This update makes the rules clearer and easier for businesses that make these important gases, saving them time and hassle. If you’re in the medical gas world, check it out and send your thoughts by April 13, 2026!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Clearer Certification Rules for Medical Gases
The FDA published a draft guidance that explains how companies must request certification for designated medical gases and what annual reports to file. The guidance describes who must submit a certification request, what information to include, and how FDA will evaluate requests; it aligns with regulations that became effective on December 18, 2025.
Defined List of Designated Medical Gases
The guidance and implementing statute identify oxygen, nitrogen, nitrous oxide, carbon dioxide, helium, medical air, and carbon monoxide as designated medical gases (DMGs). If your company manufactures, processes, packs, labels, or distributes any of these gases, those products are within the certification process described in the guidance.
Cover Letter Use and Paperwork Change
FDA recommends using a cover letter with certification requests, amendments, and supplements and plans to revise its information collection to support that practice. FDA estimates the cover letter will take about 1 hour per response and estimates 9 total annual responses, for a total estimated burden of 9 hours annually.
Form Location and Labeling Alignment
The draft guidance removes an attached certification request form and directs users to Form FDA 3864 and instructions at FDA's online forms site; it also revises labeling discussion to align with 21 CFR 201.161. These editorial and form-location changes are intended to match the revised regulations effective December 18, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-02788 — Agency Information Collection Activities: Information Collection Renewal; Comment Request; Reporting, Recordkeeping, and Disclosure Requirements Associated With Proprietary Trading and Certain Interests in and Relationships With Covered Funds
The Office of the Comptroller of the Currency (OCC) is asking for feedback on renewing paperwork rules for banks about their trading and investments in certain funds. This affects banks that do proprietary trading or have ties to covered funds, aiming to keep reporting clear and manageable. Comments are due by April 13, 2026, helping the OCC balance oversight without extra hassle or cost.
Next: 2026-02790 — 30-Day Notice of Proposed Information Collection: JADE Act Questionnaire
The Department of State wants to keep using the JADE Act Questionnaire for Burmese visa applicants, asking for public feedback over the next 30 days. About 22,800 people fill out this form yearly, spending around 30 minutes each time. This helps the government check visa eligibility while making sure the process stays clear and fair, with no extra costs or delays expected.